.World Health And Wellness Association. Being overweight and over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Health Condition Risk Element Collaboration. Worldwide styles in underweight as well as being overweight coming from 1990 to 2022: a pooled analysis of 3663 population-representative researches with 222 million little ones, adolescents, and adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Global Problem Health Condition Partners. Global, regional, and nationwide burden of diabetes from 1990 to 2021, with forecasts of incidence to 2050: an organized evaluation for the Global Trouble of Condition Research Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Globe Kidney Day Steerage Board. Obesity as well as kidney ailment: hidden repercussions of the prevalent. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
An organized evaluation and also meta-analysis proposes excessive weight forecasts start of persistent renal health condition in the basic populace. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et al. Excessive weight and also persistent renal ailment.
Are actually. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., perform Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Being overweight, renal disorder and high blood pressure: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kidney Ailment: Improving International End Results CKD Work Team.
KDIGO 2024 Scientific Practice Guideline for the evaluation and control of persistent renal ailment. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Renal Disease: Improving International Results Diabetes Mellitus Workplace Team. KDIGO 2022 Professional Process Suggestion for diabetes control in persistent renal health condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google.com Scholaru00c2.Oshima, M. et al.
Early improvement in albuminuria with canagliflozin predicts renal and cardiovascular results: a message hoc analysis from the support trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an aim at for renoprotection in clients with type 2 diabetic person nephropathy: lessons coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et al. Is actually a reduction in albuminuria associated with kidney and also cardiovascular security?
A message hoc analysis of the ALTITUDE test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney illness: a review of their kidney as well as heart security. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 as well as the kidney: from physiology to pharmacology as well as end results in diabetes.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide as well as heart end results in individuals along with type 2 diabetes mellitus. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et al. Semaglutide as well as heart results in excessive weight without diabetes mellitus. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Effects of semaglutide on severe renal condition in clients along with type 2 diabetes mellitus. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Colhoun, H. M. et cetera.
Long-term renal end results of semaglutide in weight problems and heart disease in the SELECT test. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Impacts of semaglutide on albuminuria and also kidney functionality in folks with obese or even obesity with or even without kind 2 diabetes: prolegomenous evaluation from the measure 1, 2, and 3 tests.
Diabetic issues Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Witch Doctor, A. M.
et al. Result of the glucagon-like peptide-1 receptor agonists semaglutide and also liraglutide on kidney outcomes in people with kind 2 diabetic issues: pooled evaluation of SUSTAIN 6 and LEADER. Flow 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et al.
Effect of semaglutide on kidney feature all over different amounts of guideline HbA1c, blood pressure, body system weight as well as albuminuria in SUSTAIN 6 and also trailblazer 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus the hormone insulin glargine in people along with kind 2 diabetes mellitus as well as moderate-to-severe severe kidney condition (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetes Mellitus Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Modification in albuminuria as a surrogate endpoint for progress of kidney health condition: a meta-analysis of therapy impacts in randomised scientific trials. Lancet Diabetes Mellitus Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et cetera. Impacts of semaglutide with and also without concomitant SGLT2 inhibitor use in individuals with type 2 diabetic issues and also chronic kidney illness in the circulation test. Nat.
Medication. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and safety outcomes along with GLP-1 receptor agonists alone as well as in blend with SGLT2 inhibitors in style 2 diabetes: a step-by-step testimonial as well as meta-analysis.
Circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Efficiency as well as security of SGLT2 inhibitors along with and also without glucagon-like peptide 1 receptor agonists: a SMART-C joint meta-analysis of randomised regulated trials. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of tirzepatide versus insulin glargine on kidney outcomes in style 2 diabetic issues in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 test.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et al. Body system body weight and eGFR during the course of dulaglutide procedure in style 2 diabetes as well as moderate-to-severe persistent kidney disease (AWARD-7).
Diabetes Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J. L.
et cetera. Effects of tirzepatide versus blood insulin glargine on cystatin c-based kidney functionality: a SURPASS-4 message hoc analysis. Diabetes mellitus Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetic Issues Treatment (American Diabetes mellitus Affiliation, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Results of bariatric surgery on kidney feature in obese people: a step-by-step review as well as meta evaluation.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Bilha, S. C.
et al. The impacts of bariatric surgical procedure on kidney end results: a step-by-step analysis and meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et cetera. The evaluated glomerular filtering cost (mGFR) before as well as 6 months after bariatric surgical operation: a captain research study. Nephrol.
Ther. Thirteen, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et cetera. Adiponectin minimizes glomerular endothelial glycocalyx disturbance as well as repairs glomerular barrier function in a computer mouse style of style 2 diabetes mellitus. Diabetes 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetes mellitus and also weight problems in individual illness. Realm J.
Diabetic Issues 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Determining albuminuria in people with weight problems: pitfalls of the urinary albumin-creatinine proportion. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in adults with obese or excessive weight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et cetera. A more accurate approach to approximate glomerular purification rate coming from serum creatinine: a brand new prediction equation.
Customization of Diet Regimen in Renal Health Condition Study Group. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS technique for iohexol resolve in individual EDTA and lithium-heparin blood, individual urine as well as in goat- as well as porker EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et cetera.
Efficiency and also safety of aldosterone synthase restraint along with as well as without empagliflozin for chronic renal disease: a randomised, regulated, phase 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et al. Efficiency of a novel prevention of vascular adhesion protein-1 in decreasing albuminuria in patients with diabetic person renal health condition (CD): a randomised, placebo-controlled, stage 2 test. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in combo along with dapagliflozin compared with dapagliflozin in individuals along with severe renal illness (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, clinical test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Impact of avenciguat on albuminuria in individuals along with CKD: 2 randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in patients with IgA nephropathy: a prespecified meantime evaluation as a result of a randomised, double-blind, active-controlled professional test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.